Burning cash fast, with no real prospects of a return on this excessive spending. A correction should soon come to re-rate Progen to an sp around $1.50. With the SPA now gone, and the trial at the mercy of the FDA, they are set for a tough and long road ahead. The rise of the wonder drug Nexavar needs to be factored in, yet we have not seen the sharp correction downward that is warranted. The market can not ignore the success of Nexavar for much longer. Look out below.
should head substantially lower
Add PGL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.0¢ |
Change
0.005(1.23%) |
Mkt cap ! $67.48M | |||
| Open | High | Low | Value | Volume |
| 41.0¢ | 41.0¢ | 41.0¢ | $2.725K | 6.646K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 19087 | 41.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 5531 | 2 |
View Market Depth
| Last trade - 14.06pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
41.0¢ |
Change
0.005 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 41.0¢ | 41.0¢ | 41.0¢ | 1098 | ||
| Last updated 14.06pm 24/05/2024 ? | |||||
| PGL (ASX) Chart |